CAS Key Laboratory of Separation Sciences for Analytical Chemistry, National Chromatographic R&A Center, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, China; University of Chinese Academy of Sciences, Beijing 100049, China.
Divisions of Pediatric Surgery and Pediatric Pathology, Departments of Surgery and Pathology, Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI 53226, United States of America; New York University Winthrop Hospital, Mineola, NY 11501, United States of America.
J Proteomics. 2019 Sep 30;208:103501. doi: 10.1016/j.jprot.2019.103501. Epub 2019 Aug 24.
The development of chemoresistance remains the major obstacles to successful chemotherapy of hepatocellular carcinoma. The molecular mechanisms of drug resistance are complex. Identifying the key markers is crucial for development of therapeutic strategies to overcome resistance. In this study, we employed a cell-line model consisting of the 5-fluorouracil resistant Bel/5-Fu cell line and its parental Bel cell line. Using stable isotope dimethyl labeling combined with high-resolution mass spectrometry, in total, 8272 unique proteins and 22,095 phosphorylation sites with high localization confidence were identified. Our data indicated that the GnRH signaling pathway was involved in acquiring drug resistance, which has not been well elucidated. The western blotting results confirmed that the expression levels of PLCβ3 and PLCβ3 pS1105 in Bel/5-Fu cells were increased as compared to Bel cells. Furthermore, the protein levels of SRC and PKCδ, which could phosphorylate PLCβ3 at ser1105, were higher in Bel/5-Fu cells than in Bel cells. The knockdown of SRC, PKCδ and PLCβ3 increased the susceptibility of Bel/5-Fu cells to 5-Fu. Besides, the increased transcription levels of PLCβ3, PKCδ and SRC were significantly associated with decreased overall survival. Together, our deep proteomic and phosphoproteomic data reveal novel therapeutic targets for attenuating 5-Fu resistance in anti-cancer therapy. SIGNIFICANCE: It was reported that many hepatocellular carcinoma patients are resistance to 5-Fu. Although some studies related to drug resistance have been reported, the underlying mechanisms were not well elucidated. Unlike many single molecular studies, we focused on the global proteome and phosphoproteome analysis of Bel and Bel5-/Fu cell line using stable isotope dimethyl labeling to identify the previously unrecognized signaling pathway for causing 5-Fu resistance. Our results showed that the phosphorylation levels of PLCβ3 pS1105 and the protein levels of PLCβ3, PKCδ and SRC, which are major components of GnRH signaling pathway were higher in Bel/5-Fu cells than in Bel cells. Furthermore, knockdown of PLCβ3, PKCδ and SRC increased the susceptibility of Bel/5-Fu cells to 5-Fu. Overall, this is the first comprehensive proteomic and phosphoproteomic studies on 5-Fu resistant cell line Bel/5-Fu to identify the potential targets of attenuating chemoresistance in hepatocellular carcinoma.
化疗耐药的发展仍然是肝细胞癌化疗成功的主要障碍。药物耐药的分子机制很复杂。确定关键标志物对于开发克服耐药性的治疗策略至关重要。在这项研究中,我们使用了一个由氟尿嘧啶耐药的 Bel/5-Fu 细胞系和其亲本 Bel 细胞系组成的细胞系模型。使用稳定同位素二甲基标记结合高分辨率质谱,总共鉴定出 8272 种独特的蛋白质和 22095 个具有高定位置信度的磷酸化位点。我们的数据表明,GnRH 信号通路参与了获得耐药性,这一点尚未得到很好的阐明。Western blot 结果证实,Bel/5-Fu 细胞中 PLCβ3 和 PLCβ3 pS1105 的表达水平高于 Bel 细胞。此外,在 Bel/5-Fu 细胞中,能够磷酸化 PLCβ3 丝氨酸 1105 的 SRC 和 PKCδ 的蛋白水平高于 Bel 细胞。SRC、PKCδ 和 PLCβ3 的敲低增加了 Bel/5-Fu 细胞对 5-Fu 的敏感性。此外,PLCβ3、PKCδ 和 SRC 的转录水平增加与总生存期缩短显著相关。总之,我们的深度蛋白质组学和磷酸蛋白质组学数据揭示了新的治疗靶点,可用于减轻抗癌治疗中的 5-Fu 耐药性。意义:据报道,许多肝癌患者对 5-Fu 耐药。尽管已经报道了一些与耐药性相关的研究,但潜在的机制尚未得到很好的阐明。与许多单一分子研究不同,我们使用稳定同位素二甲基标记聚焦于 Bel 和 Bel5-/Fu 细胞系的全蛋白质组和磷酸蛋白质组分析,以确定导致 5-Fu 耐药的先前未知的信号通路。我们的结果表明,Bel/5-Fu 细胞中 PLCβ3 pS1105 的磷酸化水平以及 GnRH 信号通路的主要组成部分 PLCβ3、PKCδ 和 SRC 的蛋白水平均高于 Bel 细胞。此外,PLCβ3、PKCδ 和 SRC 的敲低增加了 Bel/5-Fu 细胞对 5-Fu 的敏感性。总的来说,这是第一项关于 5-Fu 耐药细胞系 Bel/5-Fu 的全面蛋白质组学和磷酸蛋白质组学研究,旨在确定减轻肝癌化疗耐药性的潜在靶点。